Icatibant acetate,130308-48-4 (net), 138614-30-9 (acetate)
Product introduction

Product Name:Icatibant acetate


CAS No.:130308-48-4 (net), 138614-30-9 (acetate)

Catalog No.:GT-F005


Molecular Formula:C59H89N19O13S

Molecular Weight:1304.54


Icatibant acetate molecular formula

Key Specification:

Appearance: White powder
Purity(HPLC): ≥98.0%
Single Impurity(HPLC): ≤1.0%
Acetate Content(HPLC): 5.0%~12.0%
Water Content (Karl Fischer): ≤10.0%

Package: 500mg,1g, 5g, 10g, 20g, 50g, 100g, 200g, 500g



Iatibant acetate, the English name Firazyr, is a HAE treatment drug developed by Shire. It was approved by the FDA on August 25, 2011 for the treatment of acute onset of hereditary angioedema in adults aged 18 and above. It is also approved by the FDA The third drug used to treat HAE attacks.

Iatibant acetate is a super potent and selective selective competitive antagonist of bradykinin type 2 (B2) receptors. It inhibits the swelling, inflammation, and pain symptoms associated with the embolization of HAE. The harm of bradykinin treats acute HAE embolism and partial swelling.HAE is only the first of several possible indications for icatibant acetate. Other potential indications include asthma, liver cirrhosis and other types of angioedema.Therefore, icatibant acetate has high medicinal value and broad market prospects.


Storage:Cool dry place( Store at -20°C, away from the light)

Remark:For Research Use Only. Not for human use. 

Icatibant acetate APIIcatibant acetateCAS number chart

Your Name: *
E-mail: *
Verification Code:Please enter the characters in the figure below

Tel: +86-571-88211951 , 88211921. Fax:+86-571-88211907
Email: sales@gotopbio.com, Sales1@gotopbio.com
Add: Room 501, Building 1, No. 600, Yinhai Street, Qiantang New District, Hangzhou 310018, Zhejiang, P.R.China. 浙ICP备18017542号-1